NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • NIHR Oxford BRC impact
    • Steering Committee
    • Promoting equality, diversity and inclusion in research
    • Current Vacancies
    • Stay in Touch
    • Contact Us
  • Research

        • Research Overview
        • Clinical Research Facility
        • Health Economics
        • Ethics in the NIHR Oxford BRC
        • Medical Statistics
        • Infections in Oxfordshire Database (IORD)
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient and Public Involvement
    • For patients and the public
    • For researchers
    • More information
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Pre-doctoral Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • PARC Programme
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Inflammation across Tissues > First trial of a new hepatitis C vaccine shows promise

First trial of a new hepatitis C vaccine shows promise

4 January 2012 · Listed under Inflammation across Tissues, Life-saving Vaccines

A new vaccine against the chronic liver disease hepatitis C has shown promising results in a first clinical trial in humans, Oxford University researchers report.

The vaccine, based on a modified cold virus, generated immune responses similar to those seen in the minority of people who are naturally able to clear any infection with the hepatitis C virus. The findings suggest it might be possible to develop a vaccine that will be broadly effective against hepatitis C and offer lasting protection.

The researchers are hopeful that in time, this work could lead to a vaccine that protects those at risk from the disease or helps in treating those with hepatitis C infections. They caution that many more studies over a number of years would be needed in developing such a vaccine.

“We’ve found that it’s possible to prime large cellular immune responses against hepatitis C that last for at least a year,” said Professor Paul Klenerman of the Nuffield Department of Clinical Medicine at Oxford University. He added: ‘The immune responses we’ve seen are exciting and we are beginning the next stage of trials. While we are hopeful, it could be a long road to any vaccine that protects people against hepatitis C.”

Hepatitis C is a virus that constantly changes its make-up, like HIV. This makes it a very difficult target for designing a vaccine.

The Oxford researchers, along with colleagues from an Italian biotech company and the University of Birmingham, have used a new approach to stimulate a different arm of the body’s immune system from previous attempts at a vaccine. Their vaccine is designed to generate a T cell response to the more constant internal parts of the hepatitis C virus, rather than looking to prime an antibody attack on the ever-changing outer coat of the virus.

‘The outside shell of the hepatitis C virus is very variable but the inside of the virus is much more stable. That’s where the engine of the virus is, where we may be able to successfully target many of the crucial pieces of machinery,” explains Professor Klenerman. “But we need T cells and not antibodies to be able to react to the inner components of the virus.”

The study is published in the journal Science Translational Medicine. It was funded by the European Commission along with support from the UK Medical Research Council, the Wellcome Trust, the NIHR Biomedical Research Centre, Oxford and the Oxford Martin School at the University of Oxford.

The Oxford University researchers carried out a first clinical trial in humans with the new vaccine. The phase 1 study was done primarily to gain safety data on the vaccine and determine an appropriate dose and vaccination scheme. It also recorded what kind of immune response was generated. In total, 41 healthy adults participated in the study.

The vaccine appeared safe in this group: there were no significant adverse effects reported. Participants may have experienced some local pain and tenderness at the injection site, or a mild headache.

The researchers found that the vaccine could stimulate a large T cell response against hepatitis C that lasted for at least a year (the length of the study). The immune response was of a similar type and size to that reported in people who naturally clear the virus from their bodies after infection. Around one in five people are thought to clear the virus spontaneously after infection.

The immune response was broad – T cells reacted to a large range of different elements in the hepatitis C virus – and there was some response to other strains of the hepatitis C virus.

The Oxford researchers are now carrying out a trial to see if the vaccine can help treat those already infected with hepatitis C, as well as continuing to develop the vaccine to get better immune responses.

“T cell responses often become weak in those with chronic hepatitis C infections,” explains Professor Klenerman. “It may be that using a vaccine to boost their immunity could become part of any treatment with other drugs.”

A US team is also looking to carry out a larger trial in at-risk groups to see if the vaccine can offer any protection against infection with hepatitis C.

For more information please contact Professor Paul Klenerman on +44 (0)1865 281885, +44 (0)7769 861085 or [email protected] or the University of Oxford press office on +44 (0)1865 280530 or [email protected]

← Final child vaccinated in clinical trial of new TB vaccine
How has the pneumococcus bacteria evolved after the introduction of a childhood vaccine? →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Feedback

We’d love to hear your feedback. Please contact us at [email protected]

Oxford BRC on Social Media

  • Bluesky
  • Facebook
  • LinkedIn
  • Threads
  • Twitter
  • YouTube
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2025 NIHR Oxford Biomedical Research Centre